



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Anwen Liu
✉ awliu666@163.com
Yong Li
✉ liyongcsco@email.ncu.edu.cn

[†]These authors have contributed equally to this work

RECEIVED 30 July 2023
ACCEPTED 24 August 2023
PUBLISHED 06 September 2023

CITATION
Zeng Z, Qian X, Liu F, Wang Y, Yuan Y, Fang C, Zhang X, Yuan S, Chen R, Yu B, Wang T, Yin Y, Li Y and Liu A (2023) Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma. *Front. Immunol.* 14:1269596. doi: 10.3389/fimmu.2023.1269596

COPYRIGHT
© 2023 Zeng, Qian, Liu, Wang, Yuan, Fang, Zhang, Yuan, Chen, Yu, Wang, Yin, Li and Liu. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Zhimin Zeng^{1,2,3†}, Xiaoying Qian^{4,5†}, Fanrong Liu^{6†}, Yong Wang^{4,5}, Yong Yuan⁷, Chen Fang^{4,5}, Xinwei Zhang^{4,5}, Shangkun Yuan^{4,5}, Renfang Chen^{4,5}, Biao Yu^{4,5}, Tong Wang^{4,5}, Yan Yin⁸, Yong Li^{4,5*} and Anwen Liu^{1,2,3*}

¹Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China, ²Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi, China, ³Radiation Induced Heart Damage Institute of Nanchang University, Nanchang, Jiangxi, China, ⁴Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China, ⁵Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China, ⁶Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁷Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁸Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China

KEYWORDS

pulmonary sarcomatoid carcinoma, immune checkpoint inhibitors, immunotherapy, anlotinib, camrelizumab, tislelizumab

A Corrigendum on:

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.

By Zheng Z, Qian X, Liu F, Wang Y, Yuan Y, Fang C, Zhang X, Yuan S, Chen R, Yu B, Wang T, Yin Y, Li Y and Liu A (2022) *Front. Immunol.* 13:956982. doi: 10.3389/fimmu.2022.956982

In the published article, there was an error in the author list, and author Anwen Liu and Zhimin Zeng was erroneously excluded. The corrected author list appears below.

Zhimin Zeng^{1,2,3†}, Xiaoying Qian^{4,5†}, Fanrong Liu^{6†}, Yong Wang^{4,5}, Yong Yuan⁷, Chen Fang^{4,5}, Xinwei Zhang^{4,5}, Shangkun Yuan^{4,5}, Renfang Chen^{4,5}, Biao Yu^{4,5}, Tong Wang^{4,5}, Yan Yin⁸, Yong Li^{4,5*} and Anwen Liu^{1,2,3*}

The Author contributions have also been amended to: AL and YL co-designed the research. ZZ, XQ, and FL made a significant contribution to the data integration and analysis. ZZ provided patients' information and data analysis. XQ drew up the manuscript. FL and YW processed the figures and tables. YYu, CF, XZ, and SY collected the outcome. RC, BY, TW and YYi followed up on the case. All authors contributed to the article and approved the submitted version.

In the published article, there was an error. The approval of the institutional ethics committee of Second Affiliated Hospital of Nanchang University was not added to the ethics statement.

A correction has been made to Ethics statement. This sentence previously stated:

“This study was reviewed and approved by the Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University”.

The corrected sentence appears below:

“This study was reviewed and approved by the institutional ethics committee of the Second Affiliated Hospital of Nanchang University and the Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.